Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL
Recruiting · NCT06570447 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Glofitamab Combination With Chidamide in Patients With Recurrent/Refractory DLBCL | Diffuse Large B-Cell Lymphoma-Recurrent; Diffuse Large B-Cell Lymphoma-Refractory | Recruiting | Phase 2 | 2026-08-03 | NCT06570447 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Tianjin Medical University Cancer Institute and Hospital | 287 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Tianjin Medical University Cancer Insititute & Hospital | Tianjin | China | 3 |